These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 22043051)
1. Mechanisms of resistance to HER2 target therapy. Tortora G J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051 [TBL] [Abstract][Full Text] [Related]
2. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer. Sachdev JC; Jahanzeb M Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005 [TBL] [Abstract][Full Text] [Related]
4. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051 [TBL] [Abstract][Full Text] [Related]
5. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]
6. Progression and treatment of HER2-positive breast cancer. Davoli A; Hocevar BA; Brown TL Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739 [TBL] [Abstract][Full Text] [Related]
7. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer. Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964 [TBL] [Abstract][Full Text] [Related]
8. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. Spector NL; Blackwell KL J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552 [TBL] [Abstract][Full Text] [Related]
10. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer]. Lehr HA; Schaefer SC; Delaloye JF Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Nahta R; O'Regan RM Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112 [TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 for the treatment of breast cancer. Rimawi MF; Schiff R; Osborne CK Annu Rev Med; 2015; 66():111-28. PubMed ID: 25587647 [TBL] [Abstract][Full Text] [Related]
13. Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Barros FF; Powe DG; Ellis IO; Green AR Histopathology; 2010 Apr; 56(5):560-72. PubMed ID: 20459566 [TBL] [Abstract][Full Text] [Related]
14. HER2 as a target for breast cancer therapy. Tagliabue E; Balsari A; Campiglio M; Pupa SM Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497 [TBL] [Abstract][Full Text] [Related]
15. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Saxena R; Dwivedi A Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A; Colomer R; Brunet J; Menendez JA Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307 [TBL] [Abstract][Full Text] [Related]
17. Target therapy in elderly breast cancer patients. Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652 [TBL] [Abstract][Full Text] [Related]
18. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485 [TBL] [Abstract][Full Text] [Related]
19. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy. Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283 [TBL] [Abstract][Full Text] [Related]